Notable companies
The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO).
Industry description
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Market Cap
The average market capitalization across the Biotechnology Industry is 2.31B. The market cap for tickers in the group ranges from 58 to 111.05B. VRTX holds the highest valuation in this group at 111.05B. The lowest valued company is SEELQ at 58.
High and low price notable news
The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was 11%. PBM experienced the highest price growth at 222%, while AGNPF experienced the biggest fall at -90%.
Volume
The average weekly volume growth across all stocks in the Biotechnology Industry was 17%. For the same stocks of the Industry, the average monthly volume growth was -46% and the average quarterly volume growth was 38%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 83
Price Growth Rating: 54
SMR Rating: 92
Profit Risk Rating: 93
Seasonality Score: -10 (-100 ... +100)